Literature DB >> 17255361

Inhibitory effect of tumor cell-derived lactic acid on human T cells.

Karin Fischer1, Petra Hoffmann, Simon Voelkl, Norbert Meidenbauer, Julia Ammer, Matthias Edinger, Eva Gottfried, Sabine Schwarz, Gregor Rothe, Sabine Hoves, Kathrin Renner, Birgit Timischl, Andreas Mackensen, Leoni Kunz-Schughart, Reinhard Andreesen, Stefan W Krause, Marina Kreutz.   

Abstract

A characteristic feature of tumors is high production of lactic acid due to enhanced glycolysis. Here, we show a positive correlation between lactate serum levels and tumor burden in cancer patients and examine the influence of lactic acid on immune functions in vitro. Lactic acid suppressed the proliferation and cytokine production of human cytotoxic T lymphocytes (CTLs) up to 95% and led to a 50% decrease in cytotoxic activity. A 24-hour recovery period in lactic acid-free medium restored CTL function. CTLs infiltrating lactic acid-producing multicellular tumor spheroids showed a reduced cytokine production. Pretreatment of tumor spheroids with an inhibitor of lactic acid production prevented this effect. Activated T cells themselves use glycolysis and rely on the efficient secretion of lactic acid, as its intracellular accumulation disturbs their metabolism. Export by monocarboxylate transporter-1 (MCT-1) depends on a gradient between cytoplasmic and extracellular lactic acid concentrations and consequently, blockade of MCT-1 resulted in impaired CTL function. We conclude that high lactic acid concentrations in the tumor environment block lactic acid export in T cells, thereby disturbing their metabolism and function. These findings suggest that targeting this metabolic pathway in tumors is a promising strategy to enhance tumor immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255361     DOI: 10.1182/blood-2006-07-035972

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  575 in total

Review 1.  Immunologic mechanisms in RCC and allogeneic renal transplant rejection.

Authors:  Jens Bedke; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

Review 2.  Role of monocarboxylate transporters in human cancers: state of the art.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; João Azevedo-Silva; Margarida Casal; Fernando C Schmitt; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 3.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.

Authors:  Jackie E Bader; Kelsey Voss; Jeffrey C Rathmell
Journal:  Mol Cell       Date:  2020-06-18       Impact factor: 17.970

4.  The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells.

Authors:  Mengjia He; Qianni Jin; Cong Chen; Yifeng Liu; Xiangsen Ye; Yulin Jiang; Feihu Ji; Husun Qian; Delu Gan; Shujun Yue; Wei Zhu; Tingmei Chen
Journal:  Oncogene       Date:  2019-04-09       Impact factor: 9.867

5.  Emergence of spatial structure in the tumor microenvironment due to the Warburg effect.

Authors:  Carlos Carmona-Fontaine; Vanni Bucci; Leila Akkari; Maxime Deforet; Johanna A Joyce; Joao B Xavier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 6.  Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases.

Authors:  Juan Li; Tongxin Wang; Jun Xia; Weilei Yao; Feiruo Huang
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

Review 7.  Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

Authors:  John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

Review 8.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

9.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

10.  The malignant phenotype of breast cancer cells is reduced by COX-2 silencing.

Authors:  Ioannis Stasinopoulos; Noriko Mori; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.